Jerusalem, Israel, 09. Februar 2021 - Vidac Pharma Ltd. gibt den Einschluss des ersten Patienten in eine placebokontrollierte Phase-II-Studie bei frühen Formen des kutanen T-Zell-Lymphoms bekannt, der mit dem ersten Medikament seiner Klasse VDA 1102 behandelt wird. VDA 1102 unterbricht die Bindung des glykolytischen Enzyms HK2, das in Krebszellen überexprimiert ist, an den VDAC-Kanal. Dadurch wird die Apoptose (der programmierte Tod) ausgelöst und das Zellmilieu und die Zellfunktionen kehren zum normalen Verhalten zurück. VDA 1102 hat keine Auswirkungen auf normale Zellen. Diese klinische Studie findet unter der Leitung von Prof. Emilia Hodak, Leiterin der Dermatologie am Rabin Center (Beilinson) in Petach Tikva statt. Israel.
Über Vidac Pharma
Vidac ist ein privates biopharmazeutisches Unternehmen im klinischen Stadium mit Schwerpunkt Onkologie, das mit seiner bahnbrechenden metabolischen Immuno-Onkologie-Plattformtechnologie erstklassige Arzneimittel entwickelt. Vidac nutzt sein firmeneigenes Bioinformatik-Tool HEXAGON™, um Patienten mit Krebserkrankungen zu identifizieren, die hohe HK2-Werte aufweisen, und zwar bei einer Vielzahl von Tumorarten. Vidacs führendes Medikament, die VDA-1102-Salbe, befindet sich in Phase 2b zur Behandlung von aktinischer Keratose, einer frühen Form von kutanem SCC. VDA-1102 wird auch in einer parenteralen Form für die Behandlung von soliden Tumoren und hämatologischen Malignomen entwickelt, sowohl als Monotherapie als auch in Kombination.
Für weitere Informationen über Vidac Pharma besuchen Sie bitte www.vidacpharma.com.
Kontakt: Max Herzberg +972-54-425-7381
Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol 138:2635-2643), discussing the discovery of Vidac’s anti-cancer drug VDA-1102 and its pre-clinical characterization. This peer-reviewed article establishes that VDA-1102’s mechanism of action is blocking the ‘glycolysis metabolic program’ in cancer cells forcing them to undergo programmed cell death. This is supported by data from multiple laboratory systems as well as in vivo efficacy, and lack of local skin reactions, in a mouse model of UVB-induced skin cancer. VDA-1102 is now in phase 2b clinical development for treating an early form of skin cancer, known as actinic keratosis (AK) which can develop to invasive squamous cell carcinoma of the skin.
Link to the article: " A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses. "
About VDA-1102 ointment
VDA-1102 is a novel, potent selective allosteric modulator of HK2 detaching it from the mitochondria of cancer cells as well as certain immune cells. Exposure to VDA-1102 triggers apoptosis in cancer cells by detaching hexokinase 2 (HK2) from the mitochondria. The drug also leads to glycolysis inhibition, reduction of immunosuppression in the tumor microenvironment, and to stimulation of an anti-tumor immune response. The selective profile of VDA-1102, which targets malignant cells without affecting the surrounding healthy tissue, offers a broad therapeutic window. VDA-1102 is being developed as a topical ointment for treatment of actinic keratosis (AK) and other non-melanoma skin cancers. VDA-1102 ointment has successfully completed a Phase 2a proof-of-concept study in subjects with AK, demonstrating efficacy, safety, and excellent tolerability, and is now in Phase 2b trial. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.
For more information regarding Vidac Pharma, please visit www.vidacpharma.com.
Contact: Shelly Majar +972-2-5952090
###
Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach for Simultaneous Targeting of the Tumor and Its Immunosuppressive Microenvironment”, will be presented as part of the " Cellular Metabolism and Antitumor Immunity" session, on Friday, 09 November 2018 from 12:45 – 2:15 p.m. and from 6:30 – 8:00 p.m. Location: Walter E. Washington Convention Center, Exhibit Hall E, Abstract Poster Number: P197.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.
For more information please visit www.vidacpharma.com.
Contact: Shelly Majar +972-2-5952090
###
Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an early stage of cutaneous squamous cell carcinoma (cSCC), which is a common form of non-melanoma skin cancer. VDA-1102 is a selective allosteric modulator that triggers apoptosis in cancer cells by detaching hexokinase 2 (HK2) from the mitochondria. VDA-1102 is being developed as a first-in-class non-irritating topical treatment for AK, addressing a major unmet medical need because currently approved AK therapies are associated with a significant degree of local skin reactions, which can be very unsightly and burdensome to patients and lead to poor adherence to therapy.
The Phase 2b trial is a multi-center, open-label, dose-ranging study evaluating the efficacy, safety, and tolerability of daily application of topical 10% or 20% VDA-1102 ointment for 12 weeks in subjects with actinic keratosis. Subjects will be followed for one month after conclusion of treatment; the primary endpoint is percent of subjects that achieve complete clearance. The study is expected to enroll approximately 150 subjects in the US, in 2 cohorts.
“In a previous clinical proof-of-concept study (Phase 2a) VDA-1102 has demonstrated efficacy and tolerability in subjects suffering from AK,” said Chaim Brickman, MD, Vidac’s Chief Medical Officer. “We expect the current Phase 2b study to confirm these findings and establish the drug’s potential to change the landscape of AK treatments for patients suffering from this condition.”
“Vidac is committed to harness its metabolic immuno-oncology platform technology to create innovative targeted therapies for people suffering from a variety of oncological malignancies, including a variety of skin cancers,” said Dr. Oren M. Becker, Vidac’s president and CEO.
About VDA-1102 ointment
VDA-1102 is a novel, potent selective allosteric modulator of HK2 detaching it from the mitochondria of cancer cells as well as certain immune cells. Exposure to VDA-1102 triggers apoptosis in cancer cells by detaching hexokinase 2 (HK2) from the mitochondria. The drug also leads to glycolysis inhibition, reduction of immunosuppression in the tumor microenvironment, and to stimulation of an anti-tumor immune response. The selective profile of VDA-1102, which targets malignant cells without affecting the surrounding healthy tissue, offers a broad therapeutic window. VDA-1102 is being developed as a topical ointment for treatment of actinic keratosis (AK) and other non-melanoma skin cancers. VDA-1102 ointment has successfully completed a Phase 2a proof-of-concept study in subjects with AK, demonstrating efficacy, safety, and excellent tolerability, and is now in Phase 2b trial. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors.
About Actinic Keratosis
Actinic keratosis (AK) is one of the most common dermatology conditions worldwide. It effects an estimated 58 million people in the United States alone. In 2015 the global AK market was estimated at $6.6 billion. AK is considered an early form of cutaneous squamous cell carcinoma (cSCC) that occurs predominantly in older males with fair skin on areas of skin regularly exposed to sunlight. Treatment is recommended by physicians in order to prevent cSCC. It is a chronic disease for which patients often require repeat treatments. The limited tolerability (irritation) of current treatment options greatly decrease the willingness of patients to be retreated and/or compliant. As a result, patients often elect to avoid treatment, seeking medical help only after their lesions have become esthetically intolerable or have advanced to malignant cSCC tumors.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.
For more information regarding Vidac Pharma, please visit www.vidacpharma.com.
Contact: Shelly Majar +972-2-5952090
###
Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic Immuno-Oncology” at the 25th Biennial Congress of the European Association for Cancer Research (EACR25) in Amsterdam, 30 June - 03 July 2018. The poster will be presented in poster session "Tumour Immunology", on Monday, 02 July 2018 from 10:05 to 17:15 in Hall 3.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.
For more information please visit www.vidacpharma.com.
Contact: Shelly Majar +972-2-5952090
###
- VIDAC PHARMA TO PRESENT AN IMMUNO-METABOLISM POSTER AT THE 2018 AACR ANNUAL MEETING 2018
- VIDAC PHARMA TO PRESENT AT THE 2018 BIO CEO & INVESTOR CONFERENCE
- VIDAC PHARMA TO PRESENT AT THE 2018 4TH ANNUAL DERMATOLOGY INNOVATION FORUM
- VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS